Home / Stocks / Alpa Laboratories Ltd
ALPA

Alpa Laboratories Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹50.64

Change

-0.95 (-1.84%)

Open

₹51.59

Prev. Close

₹51.59

Day High

₹51.59

Day Low

₹49.21

Volume Analysis

Traded

10,939

Delivered

9,119

Delivery %

83.36%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •Low return on equity (8.38%)
  • •Below-average fundamentals quality score (45/100)
  • •Low operating margin (-0.9%)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹54.13 ₹52.86 ₹51.75 ₹50.48 ₹49.37 ₹48.1 ₹46.99
Fibonacci ₹52.86 ₹51.95 ₹51.39 ₹50.48 ₹49.57 ₹49.01 ₹48.1
Camarilla ₹51.29 ₹51.08 ₹50.86 ₹50.48 ₹50.42 ₹50.2 ₹49.99

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-35.77%

1 Week

-10.7%

1 Month

-1.13%

3 Months

-19.3%

6 Months

-26.78%

1 Year

-36.16%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹119.09

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

1.0%

Net margin 1.74% × asset turnover 0.43x × equity multiplier 1.33x

Company Overview

Sector

Healthcare

Market Cap

₹109 Cr

P/E (TTM)

52.0

ROE

8.38%

Book Value

₹88.4

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Alpa Laboratories Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 45/100. The strongest factor is Financial Strength (100/100), while Momentum (13/100) is the weakest area to weigh before deciding. Notably: Low return on equity (8.38%); below-average fundamentals quality score (45/100). FII holding has been falling.

TopFund Score — Fundamentals Quality

45/100 — Weak

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

34

Valuation

39

Cash Flow

58

Corporate Governance

56

Momentum

13

Institutional Ownership

20

Business Quality

36

Risk & Volatility

36

Liquidity

48

From Screener.in

  • +Company is almost debt free.
  • +Stock is trading at 0.59 times its book value
  • +Company's working capital requirements have reduced from 105 days to 70.6 days
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of 1.69% over past five years.
  • −Company has a low return on equity of 10.7% over last 3 years.
  • −Earnings include an other income of Rs.7.76 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Alpa Laboratories Limited hereby submit to the Exchange the Certificate under Regulation 74(5) of SEBI (Depositories and Prticipants) Regulations, 2018.

38th AGM held on 30 Sep 2026; shareholders approved financials, MD reappointment, independent director and Rs160 crore loan authority.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 32 27 24 21 25 26 40 19 26 29 31 24 31
Expenses + 29 25 20 21 22 25 40 19 29 28 28 28 33
Operating Profit 3 2 4 1 3 1 0 0 -2 2 4 -4 -2
OPM % 10.34% 8.9% 14.87% 2.47% 13.31% 2.83% 0.5% 2.25% -8.57% 5.2% 11.46% -16.55% -7.2%
Other Income + 3 4 4 5 7 9 2 12 3 1 0 6 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 1 1 1 1 1 1 1 1 1 0 1 1
Profit before tax 6 5 7 5 10 9 2 12 0 2 3 1 -2
Tax % 0.0% 14.91% 46.71% 0.0% 20.31% 0.0% 201.92% 0.0% 0.0% 9.2% 55.05% 0.0% 0.0%
Net Profit + 6 5 4 5 8 9 -2 12 0 2 1 1 -2
EPS in Rs 3 2 2 2 4 4 -1 6 0 1 1 0 -1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 139 0 -19 -16 -23 -4 69 -11 5 11 -21 25 18

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 57 53 63 62 77 85 97 112 93 109 110 106 115
Expenses + 54 47 56 58 76 80 90 101 85 100 105 103 116
Operating Profit 3 7 7 4 1 6 8 11 8 9 5 3 -1
OPM % 6.0% 13.0% 11.0% 7.0% 1.5% 7.0% 8.0% 10.0% 9.0% 8.0% 4.4% 3.1% -0.9%
Other Income + 2 5 3 5 5 0 4 11 9 14 23 16 8
Interest 2 1 2 1 1 0 0 0 0 0 0 0 0
Depreciation 6 1 3 3 3 3 1 2 1 2 2 2 2
Profit before tax -3 10 6 5 3 3 11 20 16 21 26 17 4
Tax % -48.0% 30.0% 55.0% 39.0% 63.0% 36.0% 33.0% 28.0% 21.0% 19.0% 24.0% 10.0% —
Net Profit + -1 7 3 3 1 2 7 14 13 17 20 15 2
EPS in Rs -1 3 1 1 0 1 3 7 6 8 9 7 1
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth 2 -7 19 -2 24 11 14 15 -17 17 2 -4 4

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 66 72 74 77 77 79 87 101 114 131 151 165 165
Borrowings + 29 24 11 6 2 0 0 6 2 5 0 3 1
Other Liabilities + 13 27 20 18 21 21 33 28 30 25 51 53 61
Total Liabilities 128 144 126 122 121 121 140 155 167 182 223 242 248
Fixed Assets + 5 15 15 10 8 6 7 9 7 11 21 20 21
CWIP 0 0 0 0 0 1 2 0 0 0 0 0 1
Investments 10 12 13 31 49 57 51 75 78 98 118 142 140
Other Assets + 113 118 97 81 65 58 81 71 82 73 84 80 87
Total Assets 128 144 126 122 121 121 140 155 167 182 223 242 248
Equity Capital 21 21 21 21 21 21 21 21 21 21 21 21 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -2 -22 17 -13 -1 18 -2 10 9 4 18 9
Cash from Investing Activity + 37 -8 -2 -11 -15 -11 6 -16 2 -13 -12 -11
Cash from Financing Activity + 7 -6 -15 9 -5 -1 0 5 -4 3 -5 2
Net Cash Flow 42 -36 0 -15 -20 5 4 0 7 -7 1 1
Free Cash Flow -3 -32 16 -15 -2 15 -5 8 8 -3 7 6
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -92 -277 283 -263 102 324 15 123 155 85 466 369

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 57.29% → 57.19%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 41.74% 42.21% 42.35% 41.97% 42.34% 42.3% 42.34% 42.36% 42.35% 42.43% 42.38% 42.39%
Promoters 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.19% 57.19% 57.19%
FII 0.95% 0.5% 0.36% 0.74% 0.35% 0.4% 0.36% 0.35% 0.36% 0.38% 0.35% 0.35%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.07% 0.07%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Alpa Laboratories Ltd (this stock) 109 52.0 0.59 8.38%
Vaishali Pharma Limited 95 21.4 1.33 5.83%
Parnax Lab Ltd. 125 14.6 1.27 14.2%
Bal Pharma Ltd. 135 17.1 1.58 7.79%
Sunil Healthcare Ltd. 78 26.6 1.03 6.01%
Natural Capsules Limited 144 — 0.66 -9.45%
Makers Laboratories Ltd. 169 22.6 2.15 3.17%

Which Mutual Funds Hold Alpa Laboratories Ltd?

Frequently Asked Questions about Alpa Laboratories Ltd

Community Sentiment

What are other investors saying about Alpa Laboratories Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.